Associated Papers
Glutamine antagonist DRP-104 suppresses tumor growth and enhances response to checkpoint blockade in KEAP1 mutant lung cancer.
Pillai R et al.
Science Advances, 2024
38536921 (PubMed )
Supplement: sciadv.adm9859_sm.pdf
Glutamine antagonist DRP-104 suppresses tumor growth and enhances response to checkpoint blockade in KEAP1 mutant lung cancer.
Pillai R et al.
Biorxiv : the Preprint Server for Biology, 2023
EMSY inhibits homologous recombination repair and the interferon response, promoting lung cancer immune evasion.
Marzio A et al.
Cell, 2022
KEAP1/NFE2L2 Mutations Predict Lung Cancer Radiation Resistance That Can Be Targeted by Glutaminase Inhibition.
Binkley MS et al.
Cancer Discovery, 2020
Phase and context shape the function of composite oncogenic mutations.
Gorelick AN et al.
Nature, 2020
32461694 (PubMed )
Supplement: NIHMS1582596-supplement-1582596_Supp_Tab1-5.xlsx › Table_S2._Composite_mutations
Select a paper to view details